Sigma Planning Corp Raises Holdings in uniQure (NASDAQ:QURE)

Sigma Planning Corp increased its position in shares of uniQure (NASDAQ:QUREGet Rating) by 18.8% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 48,308 shares of the biotechnology company’s stock after purchasing an additional 7,632 shares during the quarter. Sigma Planning Corp owned approximately 0.10% of uniQure worth $900,000 as of its most recent filing with the SEC.

Several other large investors have also recently made changes to their positions in the company. BlackRock Inc. increased its position in shares of uniQure by 1.7% during the first quarter. BlackRock Inc. now owns 4,366,736 shares of the biotechnology company’s stock worth $78,908,000 after purchasing an additional 72,931 shares in the last quarter. State Street Corp boosted its stake in uniQure by 30.4% during the first quarter. State Street Corp now owns 2,813,416 shares of the biotechnology company’s stock worth $50,838,000 after buying an additional 655,732 shares during the last quarter. Vanguard Group Inc. boosted its stake in uniQure by 2.5% during the first quarter. Vanguard Group Inc. now owns 1,209,840 shares of the biotechnology company’s stock worth $21,861,000 after buying an additional 30,053 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in uniQure by 22.8% during the first quarter. JPMorgan Chase & Co. now owns 884,820 shares of the biotechnology company’s stock worth $15,989,000 after buying an additional 164,069 shares during the last quarter. Finally, Privium Fund Management B.V. boosted its stake in uniQure by 4.9% during the first quarter. Privium Fund Management B.V. now owns 493,229 shares of the biotechnology company’s stock worth $8,913,000 after buying an additional 23,196 shares during the last quarter. 86.46% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other uniQure news, VP Alexander Edward Kuta III sold 2,306 shares of the company’s stock in a transaction dated Wednesday, September 21st. The stock was sold at an average price of $18.65, for a total transaction of $43,006.90. Following the sale, the vice president now owns 92,890 shares in the company, valued at approximately $1,732,398.50. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 3.10% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on QURE. The Goldman Sachs Group lowered their price objective on uniQure from $54.00 to $48.00 and set a “buy” rating on the stock in a research note on Thursday, November 3rd. Wells Fargo & Company decreased their price target on uniQure from $34.00 to $24.00 and set an “equal weight” rating on the stock in a research note on Tuesday, August 9th. TheStreet lowered uniQure from a “c-” rating to a “d” rating in a research note on Tuesday, August 9th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of uniQure in a research note on Thursday, November 3rd. Finally, Chardan Capital decreased their target price on uniQure from $65.00 to $60.00 and set a “buy” rating on the stock in a research note on Tuesday, August 9th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $45.43.

uniQure Stock Performance

QURE opened at $22.18 on Monday. The stock’s 50-day moving average price is $19.43 and its 200 day moving average price is $18.92. The company has a debt-to-equity ratio of 0.24, a current ratio of 7.26 and a quick ratio of 7.20. uniQure has a 12-month low of $12.52 and a 12-month high of $30.41.

uniQure Company Profile

(Get Rating)

uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis.

Recommended Stories

Institutional Ownership by Quarter for uniQure (NASDAQ:QURE)

Receive News & Ratings for uniQure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure and related companies with MarketBeat.com's FREE daily email newsletter.